(58 days)
Xeleris 3.1 Processing and Review Workstation (K130884)
Not Found
No
The summary describes the use of "algorithms" for automated processing and quantification, but there is no mention of AI, ML, deep learning, or any related terminology. The description of the algorithm's operation focuses on processing the dataset as a whole and enforcing constraints, which is typical of traditional image processing algorithms, not necessarily AI/ML.
No
The device is an internet-based application for processing, reviewing, and quantifying nuclear medicine cardiology medical images for diagnostic purposes, not for providing therapy.
Yes
The text explicitly states that the HeartView system can be used "for clinical diagnostic purposes, including quantitative assessments of cardiac function". It performs automated processing, review, and quantification of medical images to aid in diagnosis.
Yes
The device is described as an "internet-based application" and "software application" that processes and analyzes medical images. There is no mention of accompanying hardware components that are part of the device itself.
Based on the provided text, the HeartView system is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body, such as blood, urine, or tissue, to provide information about a person's health.
- HeartView's Function: The HeartView system processes and analyzes medical images (specifically nuclear medicine cardiology images) of radionuclides distributed within the body. It does not analyze specimens taken from the body.
- Intended Use: The intended use clearly states it's for processing, review, and quantification of medical images for clinical diagnostic purposes related to cardiac function. This is consistent with medical imaging software, not IVD.
- Device Description: The description focuses on image processing algorithms and analysis of image data, not laboratory testing of biological samples.
Therefore, the HeartView system falls under the category of medical imaging software or a medical image processing workstation, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The HeartView system is an internet-based application intended for use by nuclear medicine or r actitioners and referring physicians for the automated processing, review, quantification, and multidimensional review of nuclear medicine cardiology medical images, and specifically, radionuclides distributed in the body using planar and tomographic short axis images. HeartView may be used in various clinical settings including a hospital, clinic, imaging center, physician office, or remote locations. The HeartView system implements algorithms for automatic quantification of myocardial perfusion single photon emission computerized tomography (SPECT) as well as quantification, wall motion, and thickening from gated myocardial perfusion SPECT images. Gated results are presented as 3D plots that can be used to depict, localize, and/or quantify the distribution of radionuclide tracers and anatomical structures in scanned body tissue for clinical diagnostic purposes, including quantitative assessments of cardiac function (e.g., systolic and diastolic function, regional wall thickening, wall motion, transient ischemic dilation, and phase analysis).
Product codes (comma separated list FDA assigned to the subject device)
LLZ
Device Description
The HeartView platform is a comprehensive internet-based application designed to process, review, and automatically perform quantitative analysis of cardiac nuclear medicine procedures. HeartView implements algorithms for automatic quantification of myocardial perfusion SPECT, as well as quantification of ejection fraction, wall motion, and thickening from gated myocardial perfusion SPECT. The algorithm takes short axis slices reconstructed from raw datasets of gated and averaged acquisitions in rest and stress, and operates in multi-dimension (3D), rather than processing individual slices separately. For gated datasets, it processes the dataset as a whole rather than processing each frame separately, which adds additional knowledge to the algorithm for its computations, and allows enforcement of the constraint that the mid-myocardium volume is constant during the whole heart beat cycle.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
nuclear medicine cardiology medical images, planar and tomographic short axis images, myocardial perfusion single photon emission computerized tomography (SPECT) images, gated myocardial perfusion SPECT images.
Anatomical Site
cardiac, myocardial
Indicated Patient Age Range
Not Found
Intended User / Care Setting
nuclear medicine or radiology practitioners and referring physicians / hospital, clinic, imaging center, physician office, or remote locations.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Comparative performance testing was conducted to demonstrate that the subject device is equivalent to the predicate device for the review of nuclear studies in terms of quantitative (software-calculated values) and qualitative (subjective clinical reading) output. To support this performance claim, anonymized patient imaging studies were compared quantitatively (precision utilizing statistical software) and qualitatively (clinical review by a blinded independent cardiologist).
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Software Verification and Validation Testing: Software verification and validation testing were conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." The software for this device was considered as a "moderate" level of concern, as a malfunction of, or a latent design flaw in, the software device could lead to an erroneous diagnosis or a delay in delivery of appropriate medical care that would likely lead to minor injury. Comparative Testing: Comparative performance testing was conducted to demonstrate that the subject device is equivalent to the predicate device for the review of nuclear studies in terms of quantitative (software-calculated values) and qualitative (subjective clinical reading) output. To support this performance claim, anonymized patient imaging studies were compared quantitatively (precision utilizing statistical software) and qualitatively (clinical review by a blinded independent cardiologist). The subject device was found to be comparable to the predicate device in terms of qualitative and quantitative output.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Xeleris 3.1 Processing and Review Workstation (K130884)
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or a stylized human figure in profile, composed of three overlapping shapes.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
November 25, 2015
Vidistar, LLC % Ms. Kathryn Becker Principal Translational Science Solutions, LLC 92 Hasell Street #401 CHARLESTON SC 29401
Re: K152822
Trade/Device Name: Vidistar HeartView Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communication system Regulatory Class: II Product Code: LLZ Dated: September 29, 2015 Received: September 30, 2015
Dear Ms. Becker:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Robert Ocks
Robert Ochs. Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K152822
Device Name
VidiStar HeartView
Indications for Use (Describe)
The HeartView system is an internet-based application intended for use by nuclear medicine or ractitioners and referring physicians for the automated processing, review, quantification, and multidimensional review of nuclear medicine cardiology medical images, and specifically, radionuclides distributed in the body using planar and tomographic short axis images.
HeartView may be used in various clinical settings including a hospital, clinic, imaging center, physician office, or remote locations.
The HeartView system implements algorithms for automatic quantification of myocardial perfusion single photon emission computerized tomography (SPECT) as well as quantification, wall motion, and thickening from gated myocardial perfusion SPECT images.
Gated results are presented as 3D plots that can be used to depict, localize, and/or quantify the distribution of radionuclide tracers and anatomical structures in scanned body tissue for clinical diagnostic purposes, including quantitative assessments of cardiac function (e.g., systolic and diastolic function, regional wall thickening, wall motion, transient ischemic dilation, and phase analysis).
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(K) SUMMARY
| Submission Date: | September 24, 2015 |
|---|---|
| Submitter Information: | |
| Submitted By: | VidiStar, LLC |
| PO Box 8539 | |
| Greenville, SC 29604 | |
| Contact Person: | Craig Walker, MHA |
| Chief Executive Officer | |
| VidiStar, LLC | |
| Tel: (512) 797-1910 | |
| Fax: (864) 349-2169 | |
| Email: | craig.walker@VidiStar.com |
| Device Information: |
| Trade Name: | HeartView |
|---|---|
| Common Name: | Nuclear Medicine Workstation |
| Classification Name: | System, Image Processing, Radiological |
| 21 CFR 892.2050 | |
| Regulatory Class: | Class II |
| Product Code: | LLZ |
| Predicate Device: | Xeleris 3.1 Processing and Review Workstation (K130884) |
| GE Healthcare | |
| Class II (21 CFR 892.2050; Product Code LLZ) | |
| Device Description: | The HeartView platform is a comprehensive internet-based |
| application designed to process, review, and automatically | |
| perform quantitative analysis of cardiac nuclear medicine | |
| procedures. HeartView implements algorithms for | |
| automatic quantification of myocardial perfusion SPECT, | |
| as well as quantification of ejection fraction, wall motion, | |
| and thickening from gated myocardial perfusion SPECT. | |
| The algorithm takes short axis slices reconstructed from | |
| raw datasets of gated and averaged acquisitions in rest and | |
| stress, and operates in multi-dimension (3D), rather than | |
| processing individual slices separately. For gated datasets, |
4
| it processes the dataset as a whole rather than processing each frame separately, which adds additional knowledge to the algorithm for its computations, and allows enforcement of the constraint that the mid-myocardium volume is constant during the whole heart beat cycle. | |
|---|---|
| Intended Use: | The HeartView software application is intended to provide an automated processing, review, quantification, and multidimensional review of nuclear medicine cardiology medical images, and specifically, radionuclides distributed in the body using planar and tomographic short axis images. HeartView may be used in various clinical settings including a hospital, clinic, imaging center, physician office, or remote locations. HeartView implements algorithms for automatic quantification of myocardial perfusion single photon emission computerized tomography (SPECT) as well as quantification of ejection fraction, wall motion, and thickening from gated myocardial perfusion SPECT images. |
| Indications for Use: | The HeartView system is an internet-based application intended for use by nuclear medicine or radiology practitioners and referring physicians for the automated processing, review, quantification, and multidimensional review of nuclear medicine cardiology medical images, and specifically, radionuclides distributed in the body using planar and tomographic short axis images. |
| HeartView may be used in various clinical settings including a hospital, clinic, imaging center, physician office, or remote locations. | |
| The HeartView system implements algorithms for automatic quantification of myocardial perfusion single photon emission computerized tomography (SPECT) as well as quantification of ejection fraction, wall motion, and thickening from gated myocardial perfusion SPECT images. | |
| Gated results are presented as 3D plots that can be used to depict, localize, and/or quantify the distribution of radionuclide tracers and anatomical structures in scanned body tissue for clinical diagnostic purposes, including quantitative assessments of cardiac function (e.g., systolic | |
5
and diastolic function, regional wall thickening, wall motion, transient ischemic dilation, and phase analysis). Comparison to The device and the predicate device are both image Predicate Device post processing workstations devices that provide Technology: similar features of visualization and quantitative analysis and do not raise any new questions of safety or effectiveness. Performance Data: The following performance data were provided in support of the substantial equivalence determination: Software Verification and Software verification and validation testing were Validation Testing: conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." The software for this device was considered as a "moderate" level of concern, as a malfunction of, or a latent design flaw in, the software device could lead to an erroneous diagnosis or a delay in delivery of appropriate medical care that would likely lead to minor injury. Comparative performance testing was conducted to Comparative Testing: demonstrate that the subject device is equivalent to the predicate device for the review of nuclear studies in terms of quantitative (software-calculated values) and qualitative (subjective clinical reading) output. To support this performance claim, anonymized patient imaging studies were compared quantitatively (precision utilizing statistical software) and qualitatively (clinical review by a blinded independent cardiologist) . The subject device was found to be comparable to the predicate device in terms of qualitative and quantitative output. Additional Information: Performance Standards: The subject device is in compliance with the following voluntary performance and safety standards: . NEMA PS 3.1 - 3.20 (2011) Digital Imaging and Communications in Medicine (DICOM) Set ISO/IEC 10918-1 First edition 1994-02-15 Information . technology- Digital compression and coding of continuous-tone still images: Requirements and
6
| guidelines [including: Technical Corrigendum 1 (2005)] | |
|---|---|
| Other Standards: | The present 510(k) was prepared in consideration of the following guidance documents: |
| Guidance for the Submission of Premarket Notifications for Medical Image Management Devices (2000) Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (2005) Content of Premarket Submissions for Management of Cybersecurity in Medical Devices (2014) | |
| Conclusion: | Based on conformance to FDA recognized voluntary consensus standards, development under applicable FDA guidance, and the extensive product testing described within this 510(k) premarket notification, VidiStar provides evidence that its HeartView system is as safe and effective, and performs in a substantially equivalent manner to GE Healthcare's Xeleris 3.1 Processing and Review Workstation. |
7